狄诺塞麦医保是否可以报销?
(Denosumab) is a human monoclonal antibody, RANKL inhibitor, indicated for the treatment of osteoporosis, treatment-induced bone loss, metastasis to the bone and giant cell tumor of bone. Works by preventing the development of osteoclasts, cells that break down bone (bone resorption). On June 2, 2010, denosumab was approved by the United States (FDA) for use in postmenopausal women with the risk of osteoporosis, under the trade name Prolia.
A large phase III clinical trial in the United States for patients with newly diagnosed multiple myeloma showed that compared with zoledronic acid, denosumab is not inferior in preventing skeletal-related events and can improve the survival rate of patients, significantly reduce renal toxicity, and has good economic benefits.
The therapeutic effect of denosumab (desosumab) is amazing. Not long ago, it was officially approved for marketing in my country. As an original drug, denosumab is priced relatively high, and many patients have to bear great financial pressure.
Usually, medical insurance reimbursement is the most direct way for domestic patients to reduce the financial burden of drug purchase. So, can denosumab be reimbursed by medical insurance?
Denosumab was approved for marketing in my country in May 2019. The time to market was relatively short, and medical insurance negotiation is a complicated process. Therefore, denosumab (desosumab) is not currently covered by medical insurance and cannot be reimbursed by medical insurance.
In comparison, patients are better off buying Türkiye (Denosumab). Medical Companion Brigade learned that Turkish denosumab is also produced by Amgen, but due to local policies in Turkey, the price in Turkey is relatively low, which can greatly reduce the burden of medication on patients. The specification of Turkish denosumab is 125mg/1ml tube/box, and the price is equivalent to RMB 3,000. Patients who are convenient to go abroad can go abroad to purchase Turkish Denosumab on their own, and patients who are inconvenient to go abroad can contact domestic professional overseas medical institutions to purchase it.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)